BURBANK, CA, September 23, 2021 (GLOBE NEWSWIRE) – via NewMediaWire – Medolife Rx, Inc. (“Medolife”), an integrated global bioceutical company with R&D, manufacturing and distribution of consumer products, which is a majority-owned subsidiary of Quanta, Inc. (OTC PINK: QNTA), announced today the successful launch of a digital advertising campaign for its Aelia product line featuring product spokesperson Tony Hawk. The campaign launched nationwide on September 16, 2021 and has already garnered hundreds of thousands of impressions and resulted in increased traffic to the company’s website compared to the previous 20 days.
The company has worked with acclaimed skateboarder Tony Hawk over the past few months as a spokesperson for its Aelia pain management product line. In August, the company participated in an in-person Vert Alert event, where it showcased its products to Olympic and professional athletes across the country, as well as the general public. In mid-September, the company launched a digital advertising campaign featuring Hawk himself, which he shared with his more than 7 million followers on Instagram. In a short time, Hawk’s campaign garnered over 260,000 impressions and resulted in a significant increase in brand awareness, traffic to the e-commerce platform, and revenue generated from product sales. Since launching the campaign, the company has seen an 800% increase in unique sessions directly from Instagram. Now Medolife is working to convert that peak in visitors into sales.
“These numbers are staggering and provide proof of a tangible return on investment in our relationship with Tony Hawk,” said Medolife CEO Dr Arthur Mikaelian. “Since we launched Aelia, we have strived to promote the effectiveness and quality of our products. Working with Tony has allowed us to do just that, and the positive response we’re seeing is living proof of that. We are very fortunate to work with him and carry the message of our products to his audience of sports fans, athletes and pop culture fans across the demographic spectrum. We have so much more work with Tony and, given the success of this first campaign, I have no doubt that we have a lot more opportunities for growth and exposure working with him.
Medolife continues to plan to expand the marketing reach of its Aelia and Immunapen ™ product lines. The company will launch several new digital ads on various social media platforms in the coming days, and several product giveaway campaigns will allow more people to try the products. Medolife and Tony Hawk are also planning to host a photoshoot for Aelia products towards the end of October.
The global topical pain relief market is expected to reach $ 11.78 billion by 2025, according to an Industry Arc report. Consumer interest in this segment continues to grow, particularly among those seeking natural and more effective remedies, and the Company’s line of pain management products aligns perfectly with this trend. Its products include various formulations such as scrubs, sprays and roll-ons. All Aelia products contain ingredients that have been polarized by Medolife’s proprietary process which increases the potency of the active ingredients up to five times.
To purchase products, please visit: https://aeliastore.com/
About Medolife Rx
Medolife Rx, Inc. is a global biotechnology company engaged in clinical research, manufacturing, and consumer products. Medolife Rx was created by the merger of Medolife, a private company founded by Dr Arthur Mikaelian who pioneered the layerless polarization technology that makes the company’s pharmaceutical and nutraceutical portfolio so effective, and Quanta, Inc., a wellness product portfolio company. The Company’s main clinical development programs include Escozine®, a proprietary formulation of small molecule peptides derived from Rhopalurus princeps scorpions that is amplified by the Company’s polarization technology and is being researched for treatment for various indications, including COVID-19 and cancer. The Company has completed preclinical research into the safety and efficacy of Escozine® and continues product registration and drug approval in various countries, including the United States and throughout Latin America.
Through its subsidiary QuantRx, Medolife manufactures and distributes wellness and nutraceutical products for consumers in high-impact consumer areas such as pain relief, beauty and general well-being. QuantRx products are designed using Dr. Mikaelian’s polarization technology which applies advances in quantum biology to increase the potency of active ingredients. Currently, QuantRx supports product formulations in the areas of pain management, anti-inflammation, skin care, agriculture, nutritional supplements, and herbal consumables. Ultimately, Quanta’s mission is to deliver better, more effective ingredients to increase product effectiveness, reduce waste, and facilitate healthier, more sustainable consumption.
Beyond its own clinical and consumer applications, the polarization technology used by Medolife and its subsidiaries has many potential applications. From potentiation of bio-ingredients to the production of plants that are more effective at sequestering carbon, to transformative anti-aging solutions, Medolife has the potential to disrupt the manufacturing of commercial and pharmaceutical products and increase their benefits, all by reducing their chemical concentration.
Safe Harbor Statement under the United States Private Securities Litigation Reform Act of 1995: This press release contains forward-looking statements that express the beliefs and expectations of management, including statements regarding the results of operations or expected liquidity of the company; statements regarding projections, forecasts, expectations, estimates or forecasts regarding our business, financial and operating results and future economic performance; and statements of management’s goals and objectives and other similar expressions relating to matters which are not historical facts. In some cases, you may identify forward-looking statements by words such as “anticipate”, “estimate”, “plan”, “project”, “continue”, “in progress”, “, intend to”, ” can ”,“ will ”,“ should ”,“ could ”and similar expressions. These statements are based on current plans, estimates and expectations and involve a number of risks, uncertainties and other known and unknown factors that could cause the future results, performance or achievements of the Company. Company differ materially from the results, performance or achievements expressed or implied by these forward-looking statements. These factors and additional information are discussed in documents filed by the Company with the Securities and Exchange Commission and the statements contained in this release should be evaluated in light of these important factors. Although we believe these statements are based on reasonable assumptions, we cannot guarantee future results. Forward-looking statements speak only as of the date on which they are made, and the Company assumes no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future developments. or otherwise.